What influences cancer survivors’ participation in colorectal and breast screening

Cancer survivors face a paradox that has long puzzled oncologists and public health researchers alike. Although they belong to one of the highest-risk groups for developing new primary cancers, many of them fail to undergo the very screening tests that could catch these second malignancies early. A new systematic review and meta-analysis, published in the Journal of Cancer Survivorship, has now quantified precisely which factors determine whether cancer survivors participate in colorectal and breast cancer screening, and the findings point overwhelmingly to one conclusion: access to healthcare, more than awareness or motivation, is what separates survivors who get screened from those who do not.

The study, led by Sanjeev Bista and Hannah Harsanyi of Cancer Care Alberta and the University of Calgary, together with senior author Dylan E. O’Sullivan and an interdisciplinary team spanning oncology, medicine, and library sciences, synthesized evidence from 49 studies identified through a systematic search of MEDLINE, EMBASE, PubMed, and CINAHL from database inception through September 2024. Out of 2,492 initial citations, the researchers included studies examining predictors of colorectal cancer (CRC) screening in 35 studies and breast cancer (BC) screening in 29 studies, drawing on populations of survivors of other adult-onset cancers. Where a predictor was reported in at least three studies, the team pooled the associations using random-effects models, the standard statistical approach for meta-analyses in which true effect sizes are assumed to vary across studies because of differences in populations, settings, and measurement methods.

The biological rationale for the work is straightforward. Survivors of one cancer carry an elevated risk of subsequent primary cancers, a phenomenon documented across large registry analyses and summarized in prior meta-analyses of millions of patients. Shared genetic susceptibility, the late effects of radiation and chemotherapy, and common behavioral risk factors such as smoking all conspire to raise the incidence of second cancers above population baseline. Screening guidelines from bodies such as the International Agency for Research on Cancer and European quality-assurance programs recommend regular mammography and colorectal screening in eligible adults, and survivors, in principle, stand to gain the most. Yet uptake in this population has remained stubbornly suboptimal, and until now the evidence on why has been scattered across dozens of individually small studies.

The pooled results reveal a remarkably consistent hierarchy of predictors. For colorectal cancer screening, the strongest and most consistent associations were structural rather than psychological. Having a regular healthcare provider, possessing health insurance, and receiving an explicit recommendation from a physician were all significantly linked with higher screening participation, as was a greater number of physician visits. Demographic and socioeconomic factors mattered as well: older age, being married, higher income and education, urban residence, and White racial identity were associated with greater uptake. Behavioral and health-related factors also emerged, with nonsmokers and those reporting better mental health more likely to complete CRC screening. Each of these associations achieved statistical consistency across at least three independent studies, giving the meta-analysis unusual robustness for a field dominated by heterogeneous observational data.

For breast cancer screening, the pattern was similar but not identical. Survivors who received a written follow-up care plan, a document that typically summarizes treatments received and outlines recommended surveillance, were more likely to undergo mammography, as were those with more frequent physician visits and those receiving specialist care. Being married again emerged as a protective factor, while survivors dually enrolled in Medicaid and Medicare, a coverage status often associated with low income and complex health needs, were less likely to be screened. White racial identity was also associated with higher breast screening participation, echoing the racial disparities documented in mammography studies across the general United States population.

What makes these findings technically significant is their methodological pedigree. The review followed the PRISMA statement for systematic reviews and the MOOSE guidelines for meta-analyses of observational studies, and study quality was assessed with the Newcastle-Ottawa Scale, a widely used instrument for rating nonrandomized research. Random-effects modeling accommodates the between-study heterogeneity inherent in pooling effect estimates from different healthcare systems, survey instruments, and screening definitions. The team’s decision to quantitatively pool only predictors reported in at least three studies, rather than narratively listing every association ever measured, filters out fragile, single-study findings and isolates signals that have been independently replicated. The result is one of the most comprehensive quantitative syntheses to date of second-cancer screening behavior in survivors.

The dominance of healthcare access variables in the pooled estimates carries substantial implications for how survivorship care is organized. A provider recommendation, for example, has long been recognized as one of the most powerful levers for screening adherence in general populations, and this meta-analysis confirms that the same lever operates with particular force among survivors. Yet survivorship is precisely the phase of care in which continuity often breaks down: patients transition from active oncology treatment back to primary care, responsibilities become diffuse, and preventive services unrelated to the original cancer can fall through the cracks. The association between physician visit frequency and screening uptake in both CRC and BC analyses suggests that each clinical contact represents an opportunity for screening to be ordered, discussed, or scheduled, and that survivors with fewer contacts simply lose those opportunities.

The findings on insurance and dual Medicaid-Medicare coverage sharpen the equity dimension. Cancer survivors carry substantial healthcare expenditure burdens, and coverage gaps or fragmented insurance are known to reduce preventive service use. The meta-analysis now provides pooled evidence that this disadvantage extends specifically to subsequent cancer screening, compounding the risk profile of survivors who are already vulnerable by virtue of their cancer history. Similarly, the consistent racial disparities in both screening modalities align with broader literature documenting inequities in colorectal screening uptake by ethnicity and in mammography by race, and indicate that these disparities persist even within a population defined by shared experience of cancer diagnosis and treatment.

Mental health also emerged as a modifiable factor, with better mental health associated with colorectal screening participation. Prior studies have linked serious psychological distress and depressive symptoms, particularly among Latina and other minority survivors, with reduced preventive care use. Depression can diminish the cognitive and logistical bandwidth required to navigate appointment scheduling, transportation, and insurance authorization, and the new pooled evidence suggests that integrating mental health support into survivorship programs may yield downstream benefits for cancer prevention.

The authors are careful to frame their conclusions around what the data can and cannot show. As a synthesis of observational studies, the meta-analysis identifies associations rather than causal effects; it cannot prove, for instance, that written care plans cause higher mammography rates, only that the two reliably travel together across diverse study populations. Definitions of screening adherence varied across the included studies, as did the cancer types of the survivor populations, and the underlying primary studies were concentrated in high-income countries, particularly the United States. Nonetheless, the convergence of evidence across nearly five dozen study populations and multiple continents lends considerable weight to the central message.

That message, distilled in the paper’s implications for cancer survivors, is that interventions addressing barriers to care and the social determinants of health may be the most promising route to improving screening uptake in this high-risk population. Concretely, the evidence points toward strategies such as systematic provider recommendation protocols at every survivorship visit, routine issuance of survivorship care plans, insurance navigation support, outreach to rural and racially minoritized survivors, and screening of survivors’ mental health as part of standard follow-up. As the population of cancer survivors continues to grow globally, the challenge of preventing and detecting subsequent primary cancers will only intensify. This meta-analysis provides the clearest quantitative map yet of where the healthcare system is succeeding for survivors and, more importantly, where it is failing them.